Claims:

1. A kit, comprising *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV), particularly salts thereof, and, physically separated therefrom, a base material of a pharmaceutical agent selected from the group comprising a tablet, a capsule, a coated tablet, a suppository, an ointment, a cream, a solution for infusion and/or injection, and optionally information relating to contacting the contents of the kit, said base materials being selected in such a way that, following contacting the *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) with the base material,
   - the capsule comprises oxoplatin : silicon dioxide : mannitol or magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
   - the tablet comprises *cis*-oxoplatin : lactose : corn starch : poly(O-carboxymethyl)starch sodium salt : calcium hydrogen phosphate × $2H_2O$: cellulose powder : magnesium stearate at a ratio of 10 to 500 : 20 to 150 : 1 to 10 : 1 to 10 : 1 to 10 : 1 to 10 : 0.1 to 7; or
   - the tablet alternatively comprises *cis*-oxoplatin : silicon dioxide : magnesium stearate at a ratio of 0.1 to 10 : 0.1 to 10 : 0.1 to 10;
   - the cream comprises *cis*-oxoplatin : benzyl alcohol : cetyl stearyl alcohol : Macrogol stearate 1000 : isopropyl palmitate : glycerol : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 0.1 to 7 : 1 to 10 : 0.1 to 7 : 0.1 to 7 : 0.2 to 8 : 0.2 to 8 : 20 to 60;
   - the ointment comprises *cis*-oxoplatin : propylene glycol : Macrogol stearate 1000 : cetyl stearyl al-

cohol : vaseline at a ratio of 2 to 20 : 5 to 40 : 0.1 to 7 : 1 to 10 : 25 to 400;

- the gel comprises *cis*-oxoplatin : hydroxyethylcellulose : chloroaerosol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water at a ratio of 2 to 20 : 100 to 600 : 5 to 40 : 0.1 to 7 : 20 to 60 : 3,000 to 50,000;
- the suppository comprises *cis*-oxoplatin : silicon dioxide : hardened fat at a ratio of 0.1 to 10 : 0.1 to 10 : 30 to 300; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : highly dispersed silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 700 to 4,000 : 200 to 600 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 10; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose × $1H_2O$: corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 100 : 1,000 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7; or
- the suppository alternatively comprises *cis*-oxoplatin : lactose × $1H_2O$: corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silicon dioxide : Polysorbate 80 at a ratio of 10 to 1,000 : 1,500 to 5,000 : 300 to 1,000 : 10 to 1,000 : 10 to 1,000 : 1 to 100 : 1 to 100 : 1 to 15 : 0.1 to 7:
- the solution for injection or infusion comprises *cis*-oxoplatin : benzyl alcohol : Polysorbate 80 : 70% sorbitol solution : water at a ratio of 0.2 to 8 : 1 to 10 : 0.1 to 7 : 100 to 800 : 100 to 400; or

- the solution for injection or infusion alternatively comprises *cis*-oxoplatin : mannitol : water at a ratio of 0.1 to 7 : 5 to 40 : 1 to 10.

2. The kit according to claim 1.
characterized in that
said kit is a chemotherapeutical kit.

3. Use of the kit according to claim 1 or 2 in the production of a pharmaceutical agent for the treatment of tumors, wherein *cis*-diammoniumdichloro-*trans*-dihydroxoplatinum(IV) is incorporated in a provided base material preferably prior to application in a patient.

4. A pharmaceutical agent which can be produced by combining the components of the kit according to claim 1 or 2.

5. The pharmaceutical agent according to claim 4,
characterized in that
the capsule additionally comprises silicon dioxide and mannitol or silicon dioxide and magnesium stearate and/or pharmaceutically acceptable vehicles, especially siosomes, liposomes and/or nanocapsules.

6. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the capsule comprises 50 mg of silicon dioxide, 50 mg of mannitol or 50 mg of magnesium stearate and 50 mg of oxoplatin, or, alternatively, 50 mg of *cis*-oxoplatin, 39.5 mg of lactose or 39 mg, 2.5 mg or 2 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate $\times 2H_2O$, 2.5 mg of cellulose powder, and 0.5 mg of magnesium

stearate, or, alternatively, *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

7. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the capsule comprises 50 mg of silicon dioxide, 50 mg of mannitol or 50 mg of magnesium stearate and 50 mg of oxoplatin, or, alternatively, 50 mg of *cis*-oxoplatin, 39.5 mg of lactose or 39 mg, 2.5 mg or 2 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate × $2H_2O$, 2.5 mg of cellulose powder and 0.5 mg of magnesium stearate, or, alternatively, *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

8. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the cream comprises 50 mg of *cis*-oxoplatin, 20 mg of benzyl alcohol, 100 mg of cetyl stearyl alcohol, 25 mg of Macrogol stearate 1000, 20 mg of isopropyl palmitate, 40 mg of glycerol, 50 mg of sorbitol and 205 mg of water.

9. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the ointment comprises 50 mg of *cis*-oxoplatin, 120 mg of propylene glycol, 5.5 mg of Macrogol stearate 1000, 22 mg of cetyl stearyl alcohol, and 851.5 mg of vaseline.

10. The pharmaceutical agent according to any of the preceding claims,
characterized in that

the gel comprises 0.05 g of *cis*-oxoplatin, 1.8 g of hydroxyethylcellulose, 0.1 g of chloroaerosol, 0.005 g of sodium hydroxide, 0.17 g of sodium hydrogen phosphate dihydrate, and 97.875 g of water.

11. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the suppository comprises 0.02 g of *cis*-oxoplatin, 0.02 g of silicon dioxide and 1.85 g of hardened fat, alternatively, that the suppository comprises 20 mg of *cis*-oxoplatin, 1055, 40 mg of lactose, 170 mg of corn starch, 63.60 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80, alternatively, that the suppository comprises 20 mg of *cis*-oxoplatin, 1350 mg of lactose × $1H_2O$, 170 mg of corn starch, 65 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80, or, alternatively, that the suppository comprises 50 mg of *cis*-oxoplatin, 1450 mg of lactose×$1H_2O$, 170 mg of corn starch, 65 mg of adipic acid, 50 mg of sodium hydrogen carbonate, 5 mg of stearic acid, 4.5 mg of magnesium stearate, 3 mg of highly dispersed silicon dioxide and 0.5 mg of Polysorbate 80.

12. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the preparation of a 5 mg/ml injection or infusion solution comprises 5 mg of *cis*-oxoplatin, 9 mg of benzyl alcohol, 2 mg of Polysorbate 80, 650 mg of 70% sorbitol solution and 500 mg of water.

13. The pharmaceutical agent according to any of the preceding claims,
characterized in that
the tablet comprises 50 mg of *cis*-oxoplatin, 39.5 mg of lactose, 2.5 mg of corn starch, 2.5 mg of poly(O-carboxymethyl)starch sodium salt, 2.5 mg of calcium hydrogen phosphate × $2H_2O$, 2.5 mg of cellulose powder and 0.5 mg of magnesium stearate, or, alternatively, 50 mg of *cis*-oxoplatin, 50 mg of silicon dioxide and 50 mg of magnesium stearate.

14. Use of the pharmaceutical agent according to any of claims 4 to 13 in the prophylaxis or therapy of cancerous diseases.